Unlocking the Potential of TCR-NK Therapy for Solid Tumours

• Harnessing TCR specificity and NK-cell biology to create a differentiated approach to solid tumour targeting
• Reviewing preclinical evidence supporting anti-tumour activity, durability, and translational potential
• Sharing clinical progress and safety findings to highlight the therapeutic potential of TCR-NK therapies in patients

Speakers:

Namir Hassan

Chief Executive Officer

Zelluna